ChemDiv, Inc. operates as a discovery and development contract research organization in the United States and internationally. The company executes pre-clinical chemistry and biology for drug development and clinical trials for an international portfolio of companies across the range of targets with small molecule and biotech drugs. It specializes in early and clinical development of anti-infectives and antivirals, oncologics, CNS, cardiometabolics, and anti-inflammatory therapies. The company’s services include synthetic chemistry, structural biology and structure-based drug discovery, molecular modeling, medicinal chemistry, scale-up, biochemical and cellular assay development, analytical/...
6605 Nancy Ridge Drive
San Diego, CA 92121
Founded in 1990
ChemDiv, Inc. and Insilico Medicine, Inc. Form a Strategic Alliance to Develop Oncology Focused Libraries Using Artificial Intelligence
Sep 8 16
ChemDiv, Inc. and Insilico Medicine, Inc. announced the signing of a collaboration agreement aimed at partnering to develop and market annotated compound libraries targeting various types of cancer. These innovative libraries will advance the discovery of new oncology drug candidates. Insilico Medicine’s pharmaceutical artificial intelligence platform based on expertise in ‘omics’ data analysis and deep learning methods will add a valuable annotated component to ChemDiv’s anticancer library, and, combined with ChemDiv’s proprietary chemistry focused on small molecule drug development, will provide several thousand new oncology candidates. The first product line will contain the libraries of novel compounds against 18 types of cancer, including bladder urothelial carcinoma, breast invasive carcinoma, endocervical adenocarcinoma, colon and rectal cancer, kidney renal papillary cell carcinoma, lung adenocarcinoma, prostate adenocarcinoma, sarcoma.
ChemDiv Announces New Drug Discovery Collaboration Agreement with Cystic Fibrosis Foundation Therapeutics, Inc
May 31 16
ChemDiv announced that it has entered into a new drug discovery collaboration agreement with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). The agreement enables CFFT to use ChemDiv's unique chemistry platform to advance promising scientific research in the field of cystic fibrosis (CF) treatment. This collaboration allows ChemDiv to assist the CF clinical trials network in the world and contribute to the development of a lifelong cure for cystic fibrosis. According to the agreement, ChemDiv will provide discovery chemistry services to CFFT for their innovative research programs aimed at the development of lifesaving new therapies for cystic fibrosis.